title: Sym004: Truly a New Level of Anti-EGFR Treatment?
abstract: Sym004 is a new antibody mixture to target EGFR in metastatic colorectal cancer. Preclinical data suggest efficacy in anti-EGFR-resistant tumors, but it remains unclear whether a higher toxicity is outweighed by those advantages.
authors.affiliation: Department of Hematology and Oncology, Klinikum der Universität München, Munich, Germany. sebastian.stintzing@med.uni-muenchen.de.
authors.forename: Sebastian
authors.initials: S
authors.lastname: Stintzing
authors.affiliation: Department of Hematology and Oncology, Klinikum der Universität München, Munich, Germany.
authors.forename: Volker
authors.initials: V
authors.lastname: Heinemann
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; C569270:futuximab